Targeting β-catenin overcomes MEK inhibition resistance in colon cancer with KRAS and PIK3CA mutations

BACKGROUND: Mitogen-activated protein kinases (MEK 1/2) are central components of the RAS signalling pathway and are attractive targets for cancer therapy. These agents continue to be investigated in KRAS mutant colon cancer but are met with significant resistance. Clinical investigations have demon...

Descripción completa

Detalles Bibliográficos
Autores principales: Moon, Jai-Hee, Hong, Seung-Woo, Kim, Jeong Eun, Shin, Jae-Sik, Kim, Jin-Sun, Jung, Soo-A, Ha, Seung Hee, Lee, Seul, Kim, Joseph, Lee, Dae Hee, Park, Yoon Sun, Kim, Dong Min, Park, Sang-Soo, Hong, Jun Ki, Kim, Do Yeon, Kim, Eun Ho, Jung, Joonyee, Kim, Mi Jin, Kim, Seung-Mi, Deming, Dustin A., Kim, Kyunggon, Kim, Tae Won, Jin, Dong-Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734664/
https://www.ncbi.nlm.nih.gov/pubmed/30944457
http://dx.doi.org/10.1038/s41416-019-0434-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734664/
https://www.ncbi.nlm.nih.gov/pubmed/30944457
http://dx.doi.org/10.1038/s41416-019-0434-5

Ejemplares similares